This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Ataxia

Nemo-like kinase (NLK)

Fly and mouse studies suggest inhibiting NLK could help treat spinocerebellar ataxia type 1 (SCA1). In a fly model for SCA1, an nlk deficiency decreased markers of disease compared with no deficiency. In the fly model, expression of human NLK increased markers of disease compared with expression of a kinase-dead mutant. In a mouse model for SCA1, lower Nlk expression decreased disease-associated behaviors compared with wild-type Nlk expression. Next steps include understanding additional mechanisms downstream of NLK in diseased and normal brain function.

SciBX 6(25); doi:10.1038/scibx.2013.631
Published online June 27, 2013

Patent and licensing status undisclosed

Ju, H. et al. J. Neurosci.;
published online May 29, 2013;
doi:10.1523/JNEUROSCI.3465-12.2013
Contact: Janghoo Lim, Yale School of Medicine, New Haven, Conn.
e-mail:
janghoo.lim@yale.edu